Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation  Yi-Shan Lee, Jingxia Liu, Kristine A. Fricano, Erika M. Webb, Dan R. Toolsie, Sara Jones, James A. Rhoads, Ravi Vij, Amanda F. Cashen, Camille N. Abboud, Peter Westervelt, Nancy L. Bartlett, John F. Dipersio, Friederike H. Kreisel, Kian-Huat Lim  Biology of Blood and Marrow Transplantation  Volume 23, Issue 12, Pages 2199-2204 (December 2017) DOI: 10.1016/j.bbmt.2017.08.022 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 (A) Schematics showing definition of various survival endpoints in this study. Pretransplant PFS was defined from the date of initial diagnosis to progression before ASCT. Post-transplant PFS was defined from the date of ASCT to progression or death. Patients alive without progression were censored at the last follow-up date. OS was defined from the date of initial diagnosis to death. The alive patients were censored at the last follow-up date. Post-transplant OS was defined from the date of ASCT to death. The alive patients were censored at the last follow-up date. Survival analyses and log-rank P values of analyzed DLBCL patients stratified according to (B) MyD88 mutational status, (C) COO, or (D) IPI scores. P < .05 were considered significant. Biology of Blood and Marrow Transplantation 2017 23, 2199-2204DOI: (10.1016/j.bbmt.2017.08.022) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions